Biocept further expands its global patent estate for capturing and detecting cells that are in very low abundance and that can provide important molecular information from biological fluids
Biocept, Inc., a leading commercial provider of clinically actionable liquid biopsy tests to improve the management of cancer patients, announces that it has been awarded Australian Patent No. 2010229924 entitled, DEVICES AND METHODS OF CELL CAPTURE AND ANALYSIS. The issued patent covers the use of antibodies in microchannels for the capture of cancer cells or other cells that can be used for molecular analysis in blood and other biological fluids. Biocept has eighteen wholly-owned patents related to its core liquid biopsy technology.
Biocept’s proprietary microchannel technology enables the capture of cells that are in low abundance, such as circulating tumor cells (CTCs) shed into the blood by solid tumors, or fetal cells that are present in the maternal bloodstream.
“Our liquid biopsy platform has the distinct advantage of using both CTCs and circulating tumor DNA (ctDNA) to detect and monitor biomarkers associated with cancer,” said Lyle Arnold, Ph.D., Chief Scientific Officer at Biocept. “Antibodies are key to our microchannel technology that provides for the high-efficacy capture, visualization and microscopic analysis of target cells. We have already been granted U.S. and multiple international patents for this technology, and we are pleased to extend this protection to Australia.”
Michael Nall, Biocept’s President and CEO, added, “The granting of patents in international markets supports our activities to expand distribution of our liquid biopsy platform worldwide. Our liquid biopsy tests can provide an alternative to invasive tissue biopsies by using a simple blood sample to obtain valuable biomarker information. This information can be used by physicians to pursue personalized treatments for their patients with cancer, leading to improved outcomes.”
Source – PRNewswire